# Daratumumab Combined With Venetoclax and Dexamethasone for Newly Diagnosed Light-Chain Amyloidosis With Translocation (11;14)

> **NCT06629818** · PHASE2 · RECRUITING · sponsor: **Peking Union Medical College Hospital** · enrollment: 36 (estimated)

## Conditions studied

- Light Chain (AL) Amyloidosis

## Interventions

- **DRUG:** Daratumumab 16 mg/kg (intravenous) or Daratumumab 1800mg (subcutaneous)
- **DRUG:** Venetoclax
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT06629818
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-15
- **Primary completion:** 2026-10-14
- **Final completion:** 2026-10-14
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2025-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06629818

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06629818, "Daratumumab Combined With Venetoclax and Dexamethasone for Newly Diagnosed Light-Chain Amyloidosis With Translocation (11;14)". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT06629818. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*